Navigation Links
Medical care presents update on pharmaceutical health services research
Date:11/5/2012

Philadelphia, Pa. (November 5, 2012) - Pharmaceutical health services research goes beyond studying the effects of individual drugs, to looking at the complex and interrelated effects of medications on the health of patients and the population. The special November issue of Medical Care highlights important new papers in key areas of pharmaceutical health services research. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

The 14 papers in the special issue cover a wide range of topics related to the health effects of marketed medications, with special attention to monitoring drug safety throughout the product lifecycle. It honors the pioneering efforts of Frances O. Kelsey, MD, PhD.

Dr Kelsey is most famous as the FDA staff member who resisted approval of thalidomide, citing lack of evidence of safety of a drug later shown to be a cause of major congenital malformations. "Dr Kelsey is an icon in the history of drug development and regulationa woman of remarkable strength and insight," writes Julie M. Zito, PhD, Professor of Pharmacoepidemiology and Psychopharmacology, University of Maryland Schools of Pharmacy and Medicine, Guest Editor of the special issue.

Drug EthicsAn Emphasis on Public Health Ethics?

The lead article is an invited commentary by Howard Brody, MD, PhD, Director of the Institute for the Medical Humanities at University of Texas Medical Branch, Galveston. Traditionally, ethical issues at the intersection of medicine and the pharmaceutical industry have focused on "medical professionalism"particularly disclosing potential conflicts of interest between physician/researchers and drug companies.

But Dr Brody believes that other ethical perspectives need to be considered as well. He makes the case for a renewed emphasis on public health ethics, and specifically a more expansive approach based on social justice. He writes, "[P]ublic health practitioners have a positive duty to promote social justice related to health, especially by attending to the needs of the most vulnerable populations in society."

For example, from a public health perspective, it would be wrong for pharmaceutical companies to focus on developing drugs that will be highly profitable in wealthy countries, while neglecting diseases that affect a much larger percentage of people in poor countries that can't afford costly medications. Other issues that would come to the fore under a "public health ethical framework," include drug promotion and marketing that promotes overuse of prescription drugs; a patent system that causes "me-too" drugs rushed to market without adequate safety testing; and the lack of key safety information until after drugs are approved for marketing.

New Papers on 'Money Matters,' 'Safety Matters,' and More

Many of these issues arise in the original research papers in the special issue, which Dr Zito groups into four areas:

  • Money Matters.For example, how do low-income subsidies affect access to Medicare drug coverage? Does access to HIV drugs differ by race? How do drug company financial promotions on "off-label" use of medications.

  • Safety Matters.An update on the FDA's new "Sentinel System" using electronic health data to monitor the long-term safety of drugs after approval. Also, new studies look at the safety of antipsychotic medications in vulnerable groups of older adults.

  • Regulatory Matters.Recent improvements in the FDA's drug safety oversight of marketed medications, including the activities of a new Drug Safety and Risk Management panel; and the effects of "black box" safety warnings for an ADHD drug.

  • Quality Matters. New medication safety initiatives, such as programs to reduce prescription of "potentially inappropriate medications" in older adults and to improve drug safety in patients with chronic diseases such as diabetes.

This year marks the 50th anniversary of Dr Kelsey's receipt of the Distinguished Civilian Service Medal for preventing thalidomide's entry into the U.S. market. Throughout her long career at the FDA, Dr Kelsey planed a critical role in advancing clinical trials of medications to a higher scientific standard. Dr Zito concludes, "The broad range of clinical pharmaceutical health services/pharmacoepidemiologic research presented in this special edition underscores an important core value of Frances Kelseythat science must lead decisions in therapeutics, no matter how convinced any one stakeholder group may be of a drug's effectiveness and safety."


'/>"/>
Contact: Connie Hughes
Connie.Hughes@wolterskluwer.com
646-674-6348
Wolters Kluwer Health
Source:Eurekalert

Related medicine news :

1. Physician Groups Call for Fewer Medical Tests
2. Weill Cornell Medical College establishes Center for Healthcare Informatics and Policy
3. CAM therapy combined with conventional medical care may improve treatment of lower back pain
4. Image share project gives patients and physicians anytime, anywhere access to medical images
5. Researchers determine vitamin D blood level for reducing major medical risks in older adults
6. Biomedical researchers receive Hartwell Foundation awards
7. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
8. Fitness in Middle Age Lowers Medical Costs Later: Study
9. Ben-Gurion U. and Cincinnati Childrens Hospital to develop pediatric-specific medical technologies
10. Gene Tests May Not Drive Patients to More Medical Care
11. University studies and career expectations of medical students
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: